Diabetic Foot, Wounds, Infection Interface, and Multidisciplinary Limb-Preservation Teams

At the bedside, the practical question is whether the limb is threatened by wound extent, ischemia, infection, or some combination of all three. Chronic limb-threatening ischemia should be suspected when peripheral artery disease coexists with rest pain, gangrene, or a lower-limb ulcer of more than 2 weeks’ duration. In the diabetic foot, the threshold for formal vascular assessment should be low because neuropathy may blunt pain, medial calcification may complicate pressure interpretation, and tissue loss may progress before the patient appreciates severity. Once CLTI is suspected, the vascular surgeon should document the clinical syndrome, the duration of tissue loss, the anatomic revascularization problem, and the expected wound-healing target rather than simply recording that “PAD is present.” GVG CLTI 2019

WIfI staging gives the team a shared grammar. The Society for Vascular Surgery classification scores Wound, Ischemia, and foot Infection, each from 0 to 3, and the combined profile helps stratify amputation risk and expected revascularization benefit. In practical terms, the consult note should contain a WIfI estimate before a recommendation for revascularization, serial debridement, minor amputation, reconstruction, or major amputation is made. A prospective diabetic-foot-ulcer cohort showed that WIfI stage 4 separated amputation risk sharply from stages 1 to 3, with amputation in 62.1% of stage 4 limbs versus 6.7% in stages 1 to 3 and an adjusted odds ratio of 10.0 for stage 4; the exact risk cannot be transplanted to every health system, but the staging habit is clinically useful for communicating severity. Prospective Evaluation Society 2025 · Society Vascular Surgery 2014

The vascular surgeon should also resist the false dichotomy of “open versus endovascular” as the first decision. The first decision is whether the patient has a salvageable limb, a healing target, a revascularization target, acceptable procedural risk, and a team capable of infection control and offloading after flow is restored. BEST-CLI is important because many CLTI patients present with tissue loss: in cohort 1, among patients with adequate single-segment great saphenous vein, a bypass-first strategy lowered the composite of major adverse limb event or death compared with an endovascular-first strategy, with reported surgical-arm and endovascular-arm event rates of 42.6% and 57.4%, respectively. BEST-CLI 2022 That finding should inform judgment in suitable-vein patients, but it should not be generalized to patients without usable vein or without a wound-care and infection-control pathway that can convert perfusion into healing.

Wound healing itself is a coordinated biological process, not a dressing response. Hemostasis, inflammation, proliferation with re-epithelialization, and remodeling must occur in sequence and overlap; ischemia, persistent bacterial burden, necrotic tissue, pressure, and repetitive trauma interrupt this sequence. This explains why an ulcer may fail despite a technically satisfactory angioplasty, why antibiotics alone do not close a pressure-driven neuropathic wound, and why offloading failure can look like “poor biology” when it is actually continued mechanical injury. Staphylococcus aureus remains a central pathogen context in diabetic-foot infection discussions, and osteomyelitis associated with vascular insufficiency is a pattern commonly involving the foot in diabetes or peripheral vascular disease; definitive antibiotic selection, however, belongs to infection-specific assessment and culture-guided management. Wound Healing Cellular 2019 · Staphylococcus aureus infections 2015

Modern prediction tools may eventually refine risk assessment, but they should not replace disciplined clinical staging. Machine-learning models for wound healing and limb salvage after lower-limb revascularization are promising but methodologically heterogeneous, and current use is best confined to audit, quality improvement, and validation workflows rather than autonomous treatment selection. The senior trainee should therefore build decisions from bedside examination, WIfI stage, CLTI definition, infection severity, anatomic feasibility, conduit assessment, offloading feasibility, and the patient’s goals. After successful lower-extremity revascularization for symptomatic PAD, medical therapy also matters: in VOYAGER PAD, rivaroxaban 2.5 mg twice daily plus aspirin reduced a composite of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or cardiovascular death compared with aspirin alone, with 3-year event rates of 17.3% versus 19.9% and a hazard ratio of 0.85, while bleeding risk required individual assessment. Machine Learning Predicting 2025 · VOYAGER 2020

41.2PAD assessment in the diabetic foot — pedal perfusion, imaging, and the CLTI cross-read

Every person with diabetes and a foot ulcer deserves a vascular assessment that is more deliberate than palpating pulses. The 2023 intersocietal IWGDF/ESVS/SVS PAD pathway frames evaluation as a stepwise process: clinical examination plus ankle-brachial index or toe-brachial index, then pedal perfusion testing such as toe pressure or transcutaneous oxygen when ABI or TBI are equivocal, followed by imaging and multidisciplinary decision-making regarding revascularization and offloading. IWGDF/ESVS 2023 The vascular note should state which bedside tests were performed, whether they are interpretable, whether perfusion is adequate for healing, and what imaging is needed to plan a target arterial path.

The reason for this structure is that diabetes can make the usual screening shortcuts unreliable. A palpable pulse does not prove sufficient nutritive perfusion for a forefoot wound, and a noncompressible or misleading ankle pressure should not delay toe-level or skin-level perfusion assessment. The practical test that changes management is the one that answers the clinical question: can this wound heal with current perfusion, or does the patient need imaging and possible revascularization before definitive closure, reconstruction, or minor amputation? In documentation, avoid vague phrases such as “vascular status acceptable”; record ABI or TBI, pedal perfusion data when obtained, wound location, tissue-loss severity, and the plan for imaging or revascularization discussion. IWGDF/ESVS 2023 · Editor's Choice Intersocietal 2023

The diabetic-foot assessment should be cross-read through the CLTI lens. The Global Vascular Guidelines place WIfI staging and coordinated limb-preservation care at the center of CLTI evaluation, aligning ulcer care with imaging and revascularization planning rather than treating perfusion and wound management as separate episodes. GLASS staging grades the femoropopliteal and infrapopliteal target arterial paths and helps estimate revascularization complexity; it should be considered alongside WIfI rather than substituted for it. In practical terms, WIfI tells the team how threatened the limb is, while anatomic staging helps the vascular surgeon judge how the limb might be revascularized. GVG CLTI 2019 · GVG 2019

Classification systems should serve the clinical purpose rather than become paperwork. Wagner and University of Texas systems help communicate depth, infection, and ischemia; SINBAD supports severity scoring and benchmarking; WIfI is preferred at the revascularization and amputation-risk interface. A useful vascular service standard is to document one wound classification consistently for local communication and to add WIfI whenever PAD, tissue loss, infection, or revascularization decisions are in play. The same wound should not be described in three incompatible ways on the same admission; the resident should reconcile the wound description, infection grade, ischemia assessment, and operative plan into a single shared statement. Diabetic Foot Ulcer 2020 · Guidelines on classification 2019

Prevention and PAD assessment belong together. The IWGDF prevention framework emphasizes identification of the at-risk foot, regular inspection and risk assessment, structured patient and family education, appropriate footwear and offloading, and prompt treatment of pre-ulcerative signs. Practical Guidelines 2019 Risk stratification should be assigned and updated: category 0 is no neuropathy and no PAD with annual screening, category 1 is loss of protective sensation alone with 6-month screening, category 2 is loss of protective sensation plus PAD or deformity with 3-month screening, and category 3 is prior ulcer or amputation with review every 1 to 3 months. A patient who presents with an active ulcer has already declared high future risk; the discharge plan should therefore include the next surveillance interval and who owns it.

Diabetic-foot infection is a clinical diagnosis first, and a microbiologic problem second. The resident should decide whether the wound is uninfected, mildly infected, moderately infected, or severely infected before asking which antibiotic to prescribe. The 2023 IWGDF/IDSA scheme defines four levels: uninfected, with no local or systemic signs; mild, with at least two local signs but less than 2 cm of erythema and no systemic signs; moderate, with more than 2 cm of erythema or involvement of deeper structures without systemic inflammatory response; and severe, with systemic inflammatory response. IWGDF IDSA dfi 2023 · Infectious Diseases 2012 The severity grade should appear in the first assessment note because it drives antimicrobial intensity, oral versus intravenous route, admission need, and surgical urgency.

The post-revascularization limb remains vulnerable. VOYAGER PAD supports the concept that limb-event risk persists after technically successful lower-extremity revascularization, and that rivaroxaban 2.5 mg twice daily plus aspirin can reduce major cardiovascular and limb events compared with aspirin alone in symptomatic PAD patients after revascularization. VOYAGER 2020 In a diabetic-foot patient, that discussion should be individualized around bleeding risk, operative wounds, need for further debridement, renal function, and the likelihood of recurrent limb events. The practical point for the vascular trainee is to close the loop: revascularization is not complete until antithrombotic strategy, wound surveillance, offloading, infection follow-up, and recurrence prevention are all explicitly assigned.

The 2 cm erythema threshold is not a substitute for judgment. A plantar ulcer with minimal surface erythema but exposed tendon, deep abscess, necrotic tissue, or suspected bone involvement should not be treated as a superficial outpatient problem. Conversely, a warm neuropathic foot, Charcot change, venous edema, or postoperative inflammation can be mistaken for infection if the clinician does not examine the wound carefully. The practical documentation sequence is: local signs, erythema extent, depth or deep-structure involvement, systemic findings, perfusion status, imaging or bone evaluation when indicated by the clinical picture, culture plan when infection is established, and whether urgent source control is required. IWGDF IDSA dfi 2023 · Infectious Diseases 2012

Most clinically significant diabetic-foot infections require more than antibiotics. The historical IDSA framework established severity-graded diagnosis and treatment and emphasized that many diabetic-foot infections need surgical intervention combined with appropriate antimicrobial therapy. For the vascular surgeon, source control means removing necrotic tissue, draining abscess, opening infected compartments, addressing nonviable bone when necessary, and coordinating the timing of perfusion restoration. Antibiotics can suppress bacterial proliferation, but they do not drain pus, reverse ischemia, or offload a plantar pressure point. IWGDF IDSA dfi 2023 · Infectious Diseases 2012

Perfusion and infection severity must be interpreted together. A moderate infection in a well-perfused foot and the same infection in an ischemic forefoot are not equivalent clinical problems. Ischemia reduces antibiotic delivery, limits inflammatory response, and narrows the margin for delayed source control. When PAD coexists with infection and tissue loss, WIfI staging is the most useful communication tool because it captures wound burden, ischemia, and infection in one profile. The trainee should learn to present the case in a single sentence: “This is a diabetic neuropathic plantar forefoot ulcer with moderate infection, ischemia grade under evaluation, and suspected CLTI because the ulcer has persisted more than 2 weeks.” GVG CLTI 2019 · Society Vascular Surgery 2014

Staphylococcus aureus should remain in the surgeon’s mental model, particularly when osteomyelitis is suspected in the setting of diabetes or peripheral vascular disease, but empiric assumptions should not replace infection-specific management. Broad infectious-disease reviews support S. aureus as a core pathogen context in foot osteomyelitis associated with vascular insufficiency, while the diabetic-foot infection guideline should reference point severity, urgency, route, and culture-directed treatment. When cultures are obtained, they should be tied to a clinical question and preferably to appropriate tissue sampling after the wound is assessed, not to superficial swabs of an uninfected ulcer. IWGDF IDSA dfi 2023 · Infectious Diseases 2012 · Staphylococcus aureus infections 2015

The management endpoint is a controlled, perfused, offloaded wound with a feasible closure pathway. This may require staged debridement, minor amputation, revascularization, delayed closure, advanced reconstruction, or major amputation when limb salvage is not compatible with the patient’s physiology or goals. The vascular surgeon should be explicit about uncertainty: a severe infection may require immediate operative source control before full vascular mapping, while a stable moderate infection in an ischemic limb may allow rapid imaging and planned revascularization as part of the same limb-preservation episode. The danger is not choosing surgery or antibiotics; the danger is failing to integrate severity grade, perfusion, source control, and offloading into one plan. IWGDF IDSA dfi 2023 · GVG 2019 · Infectious Diseases 2012

41.4Offloading and the day-to-day diabetic-foot pathway

Offloading is treatment, not an accessory to treatment. For adults with diabetes and a non-infected, non-ischemic neuropathic plantar forefoot ulcer, the IWGDF 2023 offloading guideline recommends a non-removable knee-high offloading device, either a total-contact cast or a non-removable walker, as first-line therapy. IWGDF offloading 2023 Removable devices are second-line when non-removable devices are contraindicated, declined, or not tolerated. The resident should document the offloading prescription with the same seriousness as an antibiotic order: device type, removability, reason for deviation from first-line therapy, weight-bearing instructions, review interval, and who will inspect the skin.

The key caveat is that the first-line offloading recommendation applies to a specific clinical phenotype: non-infected, non-ischemic neuropathic plantar forefoot ulcers. IWGDF offloading 2023 Infection, ischemia, deformity, balance problems, falls risk, patient preference, and tolerance all change the decision. A cast that is excellent for a stable neuropathic forefoot ulcer can be unsafe if infection is evolving and daily inspection is needed, or if perfusion is inadequate and tissue injury could progress unseen. The systematic review on falls and diabetes-related foot ulcers highlights falls as an underdeveloped safety outcome, so mobility and rehabilitation risk should be assessed rather than assumed away. Systematic Review Examining 2025

The day-to-day pathway should be deliberately repetitive. At each encounter, the team should reassess wound size and depth, drainage, odor, local infection signs, erythema extent, exposed tendon or bone, offloading adherence, device-related skin injury, footwear fit, neuropathy, PAD status, and the next decision point. A 2023 systematic review of diabetic-foot-ulcer risk factors recapitulated peripheral neuropathy, PAD, prior ulceration or amputation, foot deformity, and poor glycemic control as recurring risk factors across observational studies. Diabetic foot ulcer risk factors 2023 These are not academic variables; they are the checklist that tells the clinician why the patient ulcerated and what must change to prevent recurrence.

When standard wound care, offloading, infection control, and revascularization are insufficient, reconstruction may still preserve the limb in selected patients. A 2024 systematic review of free tissue transfer for diabetic lower-limb ulcers reported limb salvage and flap survival outcomes across heterogeneous reconstructive series and supports free tissue transfer as a salvage option when durable coverage is otherwise unattainable and amputation is the alternative. Free Tissue Transfer 2025 The vascular surgeon’s contribution is to ensure inflow and outflow assessment, define the revascularization target, participate in timing decisions, and help judge whether the patient can tolerate the combined physiologic and adherence demands of reconstruction.

Multidisciplinary activation should be categorical when the clinical triggers are present. IWGDF practical guidance and PAD guidance converge on activating a diabetic-foot team when PAD is present, infection is moderate or severe, or revascularization is required to enable healing. The practical team usually includes vascular surgery, podiatry or diabetology, infectious diseases when infection complexity warrants it, wound and foot-care clinicians, and rehabilitation or orthotic support. ACC/AHA PAD 2024 · IWGDF practical 2023 The exact roster varies by institution, but the principle does not: the patient should not have to assemble limb preservation by attending disconnected appointments.

Classification supports continuity when many clinicians touch the same foot. The IWGDF classification guidance supports structured recording of wound, ischemia, infection, depth, area, and neuropathy features so multidisciplinary teams communicate risk consistently. Guidelines on classification 2019 In a busy limb-preservation service, the senior resident should make the note legible to the next clinician: where the wound is, what structure is exposed, whether infection is present and how severe it is, whether perfusion is adequate or still under evaluation, what offloading is being used, and what event will trigger escalation. “Continue dressings” is not a plan; “non-removable knee-high offloading continued because the ulcer is neuropathic, plantar, non-infected, and non-ischemic; reassess in one week for cast injury and wound progress” is a plan. IWGDF offloading 2023

41.5IWGDF 2023 and AHA/ACC/SVS 2024 — where the diabetic-foot pathway converges

The contemporary diabetic-foot pathway converges around team-based limb preservation. The 2024 ACC/AHA PAD guideline recommends multidisciplinary team-based care for patients with PAD and complex foot or limb threat, including CLTI, diabetic foot infection, ulceration, and planned revascularization, to reduce amputation and improve outcomes. ACC/AHA PAD 2024 · IWGDF practical 2023 This aligns with IWGDF diabetic-foot pathways that treat PAD, infection, offloading, wound care, and prevention as linked decisions rather than sequential referrals. For the vascular surgeon, MDT involvement should be documented as a standard element of care when CLTI, infection, ulceration with PAD, or revascularization planning is present.

The convergence is practical rather than rhetorical. A patient with a plantar neuropathic ulcer needs offloading; a patient with PAD needs perfusion assessment; a patient with moderate or severe infection needs severity-driven antimicrobial and surgical planning; a patient after revascularization needs antithrombotic review and surveillance; and a patient whose ulcer has healed needs recurrence prevention. No single specialty owns all of those tasks. The multidisciplinary system should therefore define activation triggers, clinic pathways, inpatient escalation rules, operative sequencing, discharge ownership, and recurrence surveillance intervals. ACC/AHA PAD 2024 · Practical Guidelines 2019

A useful resident habit is to present each diabetic-foot case in five domains: wound, ischemia, infection, pressure/offloading, and host risk. Wound describes size, depth, tissue loss, exposed structures, and classification. Ischemia describes pulses, ABI or TBI, pedal perfusion testing, imaging status, WIfI ischemia grade, and revascularization feasibility. Infection describes IWGDF/IDSA severity and source-control needs. Pressure describes neuropathy, deformity, device choice, adherence, and falls risk. Host risk describes prior ulcer or amputation, glycemic context, renal and cardiovascular comorbidity when known, medication issues, and ability to return for surveillance. This structure keeps the team from overvaluing the domain it knows best. IWGDF offloading 2023 · IWGDF IDSA dfi 2023 · Infectious Diseases 2012 · Guidelines on classification 2019

Wound products should not distract from fundamentals. A Cochrane review of topical antimicrobial agents for diabetic foot ulcers included 22 trials and approximately 2310 adult participants; it found low-certainty evidence that antimicrobial dressings may improve medium-term healing, but the evidence was too uncertain to establish reliable effects on infection prevention or resolution. Topical antimicrobial agents 2017 The appropriate clinical conclusion is not that topical antimicrobials are never useful, but that they should not replace debridement, perfusion assessment, infection severity grading, offloading, and follow-up. In a limb-preservation pathway, dressing selection should be subordinated to the wound’s biological and mechanical requirements.

Medication review belongs in diabetic-foot care because systemic therapies may alter cardiovascular, renal, and limb-risk tradeoffs. In the CANVAS Program, canagliflozin reduced major cardiovascular events but increased lower-extremity amputation compared with placebo, mainly at the toe or metatarsal level, with a primary cardiovascular hazard ratio of 0.86, an amputation hazard ratio of 1.97, and an amputation rate of 6.3 per 1000 patient-years in the canagliflozin group. Canagliflozin Cardiovascular Renal 2017 This is safety context rather than ulcer-treatment evidence, but it supports reviewing diabetes medications in patients with active ulcers, prior amputation, PAD, or recurrent foot complications in coordination with the diabetes team.